Adaptimmune Therapeutics plc announced the appointment of Christopher Hill as Chief Financial Officer effective September 10, 2025. Hill, with over a decade of experience in financial leadership roles within life science companies, will join from Istesso Limited where he served as CFO and COO.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptimmune Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001558370-25-011925), on September 08, 2025, and is solely responsible for the information contained therein.